Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AstraZeneca

Viking Therapeutics

Eli Lilly and Novo Nordisk aren't the only ones making anti-obesity drugs. Amgen, AstraZeneca, and Viking Therapeutics have credible candidates.

The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.

Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts project significant growth in this sector, with Amgen among key players like Novo Nordisk and Eli Lilly.

Should you buy Amgen's stock above $300?

Amgen has some compelling late-stage programs in its pipeline. Growth is likely to accelerate as the biotech makes progress.

Where Will Amgen Be in 3 Years?

Pharmaceutical regulators approved Amgen's AMGN, -1.85% Bkemv, a biosimilar to rare-disease treatment Soliris.

Amgen's rare-disease treatment biosimilar Bkemv gets FDA approval

The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris.

US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment

Data From Newly FDA-Approved IMDELLTRA™ (tarlatamab-dlle) Further Reinforce Leadership in Bispecific T-Cell Engagers Overall Survival Data from Phase 3 LUMAKRAS® (sotorasib) Plus Vectibix® (panitumumab) in Metastatic Colorectal Cancer Accepted as Late-Breaking Oral Presentation THOUSAND OAKS, Calif. , May 28, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from its broad oncology portfolio at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place from May 31-June 4 in Chicago.

AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024

Amgen has a promising entrant in the anti-obesity therapies space. Its candidate is in phase 2 trials, but there are already plans for phase 3.

Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?

American Express

Salesforce

Cisco Systems

Honeywell

McDonald's

Microsoft

Investing in Dow stocks is always a reasonable strategy for those who value the American economy. The Dow Jones is composed of 30 prominent publicly listed U.S. firms.

Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now

Amgen Inc. stock is challenging the $320 resistance level after a recent uptrend. Technical indicators suggest short-term upward momentum and strong buying pressure. EPS growth outlook and robust pipeline support the Amgen breakout from a fundamental level.

Amgen Stock: Poised To Break Out (Technical Analysis)

Amazon

Alphabet

MercadoLibre

PepsiCo

Taiwan Semiconductor Manufacturing

Walmart

If you're on the hunt for reliable blue-chip stocks to buy this month, look no further. Reliability is one of the most important factors when creating a winning investment strategy.

7 Reliable Blue-Chip Stocks That Cannot Miss

Amgen, Inc. (NASDAQ:AMGN ) ATS and the Approval of IMDELLTRA Conference Call May 20, 2024 4:00 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Murdo Gordon - Executive Vice President, Global Commercial Operations James Bradner - Executive Vice President, Research and Development Jean-Charles Soria - Senior Vice President, Global Development Oncology Susan Sweeney - Senior Vice President, Global Marketing, Access Capabilities Primal Kaur - Vice President, Global Development, Inflammation Conference Call Participants Mohit Bansal - Wells Fargo Matt Phipps - William Blair Carter Gould - Barclays Michael Yee - Jefferies Matthew Dellatorre - Goldman Sachs Evan Seigerman - BMO Capital Markets Geoff Meacham - Bank of America James Shin - Deutsche Bank Kripa Devarakonda - Truist Securities Gary Nachman - Raymond James Operator My name is Julianne and I'll be your conference facilitator today for Amgen's Conference Call Following The American Thoracic Society 2024 International Conference and the Approval of IMDELLTRA. All lines have been placed on mute to prevent any background noise.

Amgen, Inc. (AMGN) ATS and the Approval of IMDELLTRA Conference - (Transcript)

Genmab - ADR

Novo Nordisk

Regeneron Pharmaceuticals

Bio-Techne

United Therapeutics

Fundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying prioritization. While the media focuses on attaining wealth, that doesn't mean much if you don't have health.

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels THOUSAND OAKS, Calif. , May 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, chronic bronchitis or smoking status.

NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD

Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.

Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC

Altimmune

Roche Holding AG

Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.

4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly

Wegovy and Zepbound are two of the hottest GLP-1 drugs available on the market right now. The field, however, could become more crowded as more companies develop rival treatments.

Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk

Amgen AMGN, -0.65% on Thursday received approval from U.S. regulators for its drug to treat a form of late-stage lung-cancer.

Amgen gets FDA approval for small-cell lung-cancer treatment

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor IMDELLTRA Demonstrated Impressive 40% Objective Response Rate, 9.7 Month Median Duration of Response and 14.3 Month Median Overall Survival in Pivotal DeLLphi-301 Study Amgen to Host Webcast Investor Call on May 20, 2024 at 1:00 p.m. PT THOUSAND OAKS, Calif.

FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

The FDA cleared the Amgen drug, called Imdelltra, as a treatment for patients with advanced small-cell lung cancer.

FDA approves Amgen's treatment for most deadly form of lung cancer

The U.S. Food and Drug Administration has granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for treating adults with advanced small cell lung cancer that has worsened despite chemotherapy, Bloomberg News reported on Thursday.

US FDA approves Amgen drug for small cell lung cancer, Bloomberg reports

Remember when the Federal Reserve stopped printing money for a few months? It didn't go well.

The Best Dividend Stocks For A Dovish Fed

THOUSAND OAKS, Calif. , May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m.

AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024

Amgen Inc. (NASDAQ:AMGN ) BofA Securities 2024 Health Care Conference May 14, 2024 ET Company Participants Peter Griffith - EVP & CFO James Bradner - EVP, Research and Development & Chief Scientific Officer Justin Claeys - VP, IR Conference Call Participants Geoff Meacham - BofA Securities Peter Griffith [Call Starts Abruptly] for the Phase II study is complete and that we are confident in MariTide's differentiated profile and are actively planning a broad Phase 3 program, including obesity, obesity-related conditions, and diabetes. We've also initiated activities to further expand manufacturing capacity with both clinical and commercial supply in mind.

Amgen Inc. (AMGN) BofA Securities 2024 Health Care Conference (Transcript)

Goldman Sachs

The Dow Jones Industrial Average is on a hot streak, rising each of the first nine days of May. According to Barron's, only three of the index's 30 components — Intel (NASDAQ: INTC ), Disney (NYSE: DIS ) and McDonald's (NYSE: MCD ) — dropped in that time.

The 3 Best Dow Stocks to Buy in May 2024

Eli Lilly

Given its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ NASDAQ : AMGN). Both stocks have been in the limelight lately, given their focus on the lucrative weight-loss treatment market.

News for Amgen Stock (AMGN)